MRUS - Merus N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Merus N.V.

Yalelaan 62
Utrecht 3584 CM
Netherlands
31 30 253 8800
http://www.merus.nl

SectorHealthcare
IndustryBiotechnology
Full Time Employees97

Key Executives

NameTitlePayExercisedYear Born
Dr. Ton LogtenbergPres, CEO, Principal Financial Officer & Exec. DirectorN/AN/A1958
Mr. John de Kruif Ph.D.CTO & Sr. VPN/AN/A1964
Mr. Mark Throsby Ph.D.Chief Scientific Officer & Exec. VPN/AN/A1967
Mr. Peter B. Silverman J.D.Exec. VP, Gen. Counsel & Chief Intellectual Property OfficerN/AN/A1978
Mr. Alexander Berthold Hendirk Bakker Ph.D.CDO & Sr. VPN/AN/A1967
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II clinical trial for the treatment of gastric and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for the treatment of solid tumors with an initial focus on colorectal cancer. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore new potential combination therapies or indication. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Corporate Governance

Merus N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.